SCHEMBL4146948

SCHEMBL4146948

CCC1CCCCN1C(=O)c1ccc(N2CCC3(CC2)CCN(C2CCC2)CC3)nc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 5/20 0.46
GRM5 P41594 4/20 0.44
HRH3 Q9Y5N1 6/20 0.44
KDM4E B2RXH2 2/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
HSD11B1 P28845 1/20 0.39
L3MBTL3 Q96JM7 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4125834 0.87 HPGD (0.51) ADRA1AGRM5HRH3KDM4ELMNA
SCHEMBL4131457 0.87 ADRA1A (0.51) ADRA1AHRH3ALDH1A1POLB
SCHEMBL4936130 0.87 ADRA1A (0.51) ADRA1AHRH3ALDH1A1POLB
SCHEMBL4130761 0.85 L3MBTL3 (0.47) GRM5HRH3KDM4ELMNAMAPT
SCHEMBL4137004 0.84 ADRA1A (0.53) ADRA1AGRM5HRH3HPGD
SCHEMBL3771076 0.83 HRH3 (0.47) ADRA1AGRM5HRH3KDM4ELMNA
SCHEMBL4433768 0.83 ADRA1A (0.57) ADRA1AHRH3KDM4EL3MBTL3L3MBTL1
SCHEMBL4130774 0.82 ALDH1A1 (0.59) ADRA1AHRH3KDM4EL3MBTL3L3MBTL1
SCHEMBL4140037 0.82 ALDH1A1 (0.59) ADRA1AHRH3KDM4EL3MBTL3L3MBTL1
SCHEMBL4936546 0.81 HRH3 (0.64) ADRA1AHRH3MAPTALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021004-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2009-02-11 EP claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US claimed
WO-2007133561-A2 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION (US) 2007-11-22 WO claimed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES NEUROGEN CORPORATION 2008-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247964-A1 SUBSTITUTED AZASPIRO DERIVATIVES HRH3, HRH4, HRH1 ADRA1A 420/4885GRM5 91/4885HRH3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.